Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.07 · 8-K

PepGen Inc.

PEPGNASDAQEQUITYCurrent

Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) of PepGen Inc. (the “Company”) was held on June 18, 2026.…

Filed Jun 22, 2026Accepted Jun 22, 2026, 4:30 PM EDTCIK 1835597Accession 0001193125-26-277579
Share

Company context

PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, PepGen is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.

Current securities

Recent company filings

  1. Results of Operations and Financial Condition · Regulation FD Disclosure · Other EventsAug 6, 2026
  2. 10-Q filingAug 6, 2026
  3. 4 filingJun 22, 2026
  4. 4 filingJun 22, 2026
  5. EFFECT filingMay 21, 2026

Registered securities in this filing

PepGen Inc. · 8-K · Filed 2026-06-22

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, par value $0.0001 per share

Symbol
PEPG
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_f976a466-a309-44ef-9156-ea173733b99b

Dimensions: Not supplied

Accession 000119312526277579 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.07

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders. The 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) of PepGen Inc. (the “Company”) was held on June 18, 2026. The proposals set forth below were submitted to the stockholders at the 2026 Annual Meeting, with each such proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2026 in connection with the 2026 Annual Meeting. The number of shares of common stock entitled to vote at the 2026 Annual Meeting was 69,169,215. The number of shares of common stock present or represented by valid proxy at the 2026 Annual Meeting was 54,650,845. Therefore, a quorum was present. The number of votes cast for and withheld/against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below. Proposal 1 - Election of Directors The Company’s stockholders elected the three Class I directors to the Company’s board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Director Nominee Votes For Votes Withheld ──────────────────────────────────────────────────────────────────── Howard Mayer, M.D. 36,111,969 8,502,248 Joshua Resnick, M.D., M.B.A. 35,766,232 8,847,985 Lisa Wyman, M.S. 39,423,497 5,190,720 There were 10,036,628 broker non-votes regarding the election of each of Howard Mayer, Joshua Resnick, and Lisa Wyman. Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions ────────────────────────────────────────────────── 54,556,255 77,083 17,507 There were zero broker non-votes regarding this proposal.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.